Trial · NCT07907601
Impact of Multidisciplinary Care, Structured and Targeted on the COPD Patient's Clinical Pathway.
NCT07907601, Not applicable, Not yet recruiting, Centre Hospitalier Universitaire de Nīmes
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Impact of Multidisciplinary Care, Structured and Targeted on the COPD Patient's Clinical Pathway. Trials, record NCT07907601. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07907601
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Impact of Multidisciplinary Care, Structured and Targeted on the COPD Patient's Clinical Pathway.
- NCT number
- NCT07907601
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 116 participants, estimated
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Conditions
- Chronic Obstructive Pulmonary Disease, Lung Diseases, Obstructive, Lung Disease Chronic
- Interventions
- COPD targeted pharmaceutical interview and consultation, Respiratory Insufficiency Day Hospitalization, Pulmonary Function Test
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes46
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Impact of a targeted and multidisciplinary approach on the quality of life of COPD patients at 12-month follow-up. Control group | Baseline | Difference between the quality-of-life score based on the BPCO-VQ-11 questionnaire given at inclusion and after 12-month follow-up. A first questionnaire will be completed by the patient at inclusion, directly in the care department. A second questionnaire will be completed by the patient at 12 months, during a follow-up visit for consultation with an advanced practice nurse. |
| Primary | Impact of a targeted and multidisciplinary approach on the quality of life of COPD patients at 12-month follow-up. Experimental group | Baseline | Difference between the quality-of-life score based on the BPCO-VQ-11 questionnaire given at inclusion and after 12-month follow-up. A first questionnaire will be completed by the patient at inclusion, directly in the care department. A second questionnaire will be completed by the patient at 12 months, during a follow-up visit for consultation with an advanced practice nurse. |
| Primary | Impact of a targeted and multidisciplinary approach on the quality of life of COPD patients at 12-month follow-up. Control group | At 12 months | Difference between the quality-of-life score based on the BPCO-VQ-11 questionnaire given at inclusion and after 12-month follow-up. A first questionnaire will be completed by the patient at inclusion, directly in the care department. A second questionnaire will be completed by the patient at 12 months, during a follow-up visit for consultation with an advanced practice nurse. |
| Primary | Impact of a targeted and multidisciplinary approach on the quality of life of COPD patients at 12-month follow-up. Experimental group | At 12 months | Difference between the quality-of-life score based on the BPCO-VQ-11 questionnaire given at inclusion and after 12-month follow-up. A first questionnaire will be completed by the patient at inclusion, directly in the care department. A second questionnaire will be completed by the patient at 12 months, during a follow-up visit for consultation with an advanced practice nurse. |
| Secondary | A. Forced Expiratory Volume in 1 second in the control group | Baseline | Spirometry |
| Secondary | A. Forced Expiratory Volume in 1 second in the experimental group | Baseline | Spirometry |
| Secondary | A. Forced Expiratory Volume in 1 second in the control group | At 12 months | Spirometry |
| Secondary | A. Forced Expiratory Volume in 1 second in the experimental group | At 12 months | Spirometry |
| Secondary | B.Dyspnea in the control group according to the Modified Medical Research Council (mMRC) scale in the control group | Baseline | The Modified Medical Research Council (mMRC) scale is a self-administered scale ranging from 0 to 4, by means of which patients evaluate their breathlessness as follows: 0 I only get breathless with strenuous exercise 1. I get short of breath when hurrying on level ground or walking up a slight hill 2. On level ground, I walk slower than people of the same age because of breathlessness, or have to stop for breath when walking at my own pace 3. I stop for breath after walking about 100 yards \[91 meters\] or after a few minutes on level ground 4. I am too breathless to leave the house or I am breathless when dressing |
| Secondary | B.Dyspnea in the control group according to the Modified Medical Research Council (mMRC) scale in the experimental group | Baseline | The Modified Medical Research Council (mMRC) scale is a self-administered scale ranging from 0 to 4, by means of which patients evaluate their breathlessness as follows: 0 I only get breathless with strenuous exercise 1. I get short of breath when hurrying on level ground or walking up a slight hill 2. On level ground, I walk slower than people of the same age because of breathlessness, or have to stop for breath when walking at my own pace 3. I stop for breath after walking about 100 yards \[91 meters\] or after a few minutes on level ground 4. I am too breathless to leave the house or I am breathless when dressing |
1 to 10 of 46Source ClinicalTrials.gov
See all 46 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07907601
GET https://conductscience.org/api/trials/v1/NCT07907601/registered?page=2